Amphastar Pharmaceuticals, Inc. 8-K

What Happened Amphastar Pharmaceuticals, Inc. (filed 8‑K on June 3, 2026) announced voting results from its Annual Meeting. Three Class I directors — David Gaugh, William J. Peters and Jacob Liawatidewi — were elected to serve until the 2029 annual meeting. Stockholders also ratified Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal 2026, approved the compensation of named executive officers in a non‑binding “say‑on‑pay” vote, and chose an annual frequency for future advisory votes on executive compensation.

Key Details

• Directors elected to serve until 2029:
  • David Gaugh: For 35,242,863; Against 209,084; Abstained 25,045; Broker non‑votes 4,439,978.
  • William J. Peters: For 23,652,131; Against 11,785,772; Abstained 39,089; Broker non‑votes 4,439,978.
  • Jacob Liawatidewi: For 23,224,791; Against 12,212,988; Abstained 39,213; Broker non‑votes 4,439,978.
• Auditor ratified: Ernst & Young LLP — For 39,179,786; Against 684,828; Abstained 52,356.
• Say‑on‑pay (advisory) approved: For 32,585,908; Against 2,779,281; Abstained 111,803; Broker non‑votes 4,439,978.
• Say‑on‑frequency approved as annual: 1 Year — 33,816,071; 2 Years — 12,329; 3 Years — 1,624,016; Abstained 24,576. The board will hold advisory votes on executive compensation every year; the next required advisory vote on frequency is no later than the 2032 annual meeting.

Why It Matters These results confirm the board’s composition and continuity through 2029, which affects corporate governance and oversight. Ratifying Ernst & Young LLP sets the auditor for Amphastar’s 2026 financial reporting. The approved non‑binding say‑on‑pay and the decision to hold annual advisory votes keep the company’s executive compensation practices under regular shareholder review, which investors watch as part of governance and oversight of management.